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Abstract
To identify genetic changes that lead to the attenuation of measles virus (MV), a strain of MV that is pathogenic in rhesus macaques was
adapted to grow in Vero cells, Vero/hSLAM cells and, to simulate the process used to derive live attenuated vaccines, in primary chicken embryo
fibroblasts (CEF). Comparison of the complete genomic sequences of the pathogenic wild-type (Davis87-wt) and four cell culture-adapted strains
derived from it showed complete conservation of sequence in the Vero/hSLAM-passaged virus. Viruses adapted to Vero cells and CEF had
predicted amino acid changes in the nucleocapsid protein, phosphoprotein, V protein, C protein, matrix protein, and the cytoplasmic tail of the
hemagglutinin protein. All four cell culture-adapted strains, including the Vero/hSLAM cell-passaged virus, were able to productively infect Vero
cells, but the peak viral titers differed. The Vero cell-adapted strains were unable to replicate in Chinese Hamster Ovary cells expressing CD46,
indicating that they had not adapted to use the CD46 receptor. The Vero/hSLAM cell-passaged virus retained pathogenicity in rhesus macaques as
measured by the appearance of a skin rash while the Vero cell-adapted and CEF-adapted strains had lost the ability to cause a rash. There were no
significant differences in viral titers in peripheral blood mononuclear cells among monkeys infected with any of the viral stocks tested. These
results identify a limited number of genetic changes in the genome of MV that lead to attenuation in vivo.
© 2007 Elsevier Inc. All rights reserved.Keywords: Measles; Cell culture adaptation; Pathogenesis; Rhesus; AttenuationIntroduction
The widespread use of live attenuated measles vaccines has
resulted in a dramatic reduction in the global morbidity and
mortality caused by measles infections (Anonymous, 2006;
Wolfson et al., 2007). The live-attenuated measles vaccines that
are in use today have outstanding safety and efficacy profiles;
however, the genetic basis for the attenuation of measles virus
(MV) vaccine strains is unknown. Many of the current vaccine
strains were derived from the prototype Edmonston isolate,
while others were derived from unrelated wild-type viruses
(Rota et al., 1994). All of the vaccines were developed well in
advance of modern molecular biologic techniques and the⁎ Corresponding author. Centers for Disease Control and Prevention, Mail-
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doi:10.1016/j.virol.2007.11.025genetic characterization of vaccine viruses has been a relatively
recent activity. The WHO currently recognizes 23 genotypes of
MV (WHO, 2005), and all of the vaccine strains are members of
genotype A. Comparison of the sequences of the complete
genomes of all of the Edmonston-derived vaccine strains with
the sequence of the Edmonston wt virus (Ed-wt) (Parks et al.,
2001a,b) identified a limited number of nucleotide substitutions
in the vaccine strains relative to Ed-wt. However, the stock of
Ed-wt had been passaged 13 times in cell culture prior to the
sequence analysis (Rota et al., 1994). Since the original clinical
specimen for Ed-wt is not available for sequence analysis, a
direct comparison of the genomic sequences of the wild-type
virus and vaccine strains is not possible.
There have been no reports of measles outbreaks associated
with genotype A in the last two decades, but genotype Aviruses
have been associated with a small number of sporadic cases
(Riddell et al., 2005). Because many of these events could be
Table 1
Passage history and viral titers of cell culture-adapted virus stocks used in this
study
Virus
stock
Passaged
on
Source for
infection
Number of
passages
Titer on Vero/
hSLAM cells
D-V/S Vero/
hSLAM
Davis87-wt 9 2.1×107 pfu/ml
D-VI Vero Davis87-wt 19 9.2×107 pfu/ml
D-VII Vero Davis87-wt 12 2.9×107 pfu/ml
D-CEF CEF D-V/S 21 4.0×107 pfu/ml
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reactions, the identification of genomic markers for attenuation
of MV would facilitate surveillance for wild-type MVs. In
addition, this genetic information could be used to monitor the
safety and stability of new vaccine lots and would contribute to
the development of improved vaccines for MV.
MV is a member of the genus Morbillivirus of the family
Paramyxoviridae. Its monopartite, single-stranded, negative-
sense RNA genome contains six genes, which encode eight
proteins (Griffin, 2001). The noncoding regions of the termini
contain the promoters for transcription and replication and the
encapsidation signals. The nucleoprotein (N) encapsidates the
viral genome and binds the polymerase complex. The P gene
encodes three proteins, the phosphoprotein (P) and the C and V
proteins. C is translated from an overlapping reading frame
while V shares an amino terminal domain of 231 amino acids
with P, but has a unique carboxyl terminus as a result of RNA
editing (Cattaneo et al., 1989). P is a necessary component of
the polymerase complex and acts as a scaffolding protein in
nucleocapsid assembly. The C and V proteins regulate
polymerase activity (Bankamp et al., 2005; Reutter et al.,
2001; Tober et al., 1998; Witko et al., 2006) and act as
antagonists of the innate immune response (Shaffer et al., 2003;
Takeuchi et al., 2003). The matrix protein (M) plays a role in
viral assembly and in the transport of viral glycoproteins to the
apical membrane of polarized cells (Naim et al., 2000). The
fusion (F) and hemagglutinin (H) glycoproteins are expressed
on the surface of infected cells and of the virion, where the F
protein promotes fusion with adjacent membranes. The H
protein binds to specific receptors on the host cell and is a
required co-factor for fusion. The Large protein (L) is the
catalytic subunit of the polymerase complex.
Two cellular receptors for MV have been characterized to
date, CD46 (Membrane Cofactor Protein) (Dorig et al., 1993;
Naniche et al., 1993) and signaling lymphocyte activation
molecule (SLAM) (Tatsuo et al., 2000). SLAM serves as a
receptor for all wild-type isolates of MVas well as cell culture-
adapted strains but is only expressed on a subset of cells of the
immune system (Erlenhoefer et al., 2001; Hsu et al., 2001; Ono
et al., 2001). CD46 is expressed on all nucleated human cells,
including the epithelial surfaces of the respiratory tract, where
MV infections are thought to initiate (Liszewski et al., 1991).
However, CD46 can serve as a high affinity receptor only for
cell culture-adapted, especially Vero cell-adapted MV strains
(Buckland and Wild, 1997). Vero cells (African green monkey
kidney cells) express a CD46 homologue, as do the cells of
other Old World monkeys (Hsu et al., 1997), including rhesus
macaques. However, Vero cells do not express SLAM. The
sensitivity of isolation of MV from clinical samples has been
greatly improved because of the recent development of Vero/
hSLAM cells (Ono et al., 2001). Chicken embryo fibroblasts
(CEF), which were used to generate many of the currently used
measles vaccines (Rota et al., 1994), do not express either of the
two known receptors for MV (Yanagi et al., 2002). Past attempts
to characterize nucleotide changes induced by adaptation to cell
culture have focused on Vero cells, while little is known about
adaptation of MV to avian cells.Rhesus macaques are an excellent animal model for measles
infections, since they reproduce most of the pathologic and
immunologic aspects of the human disease (El Mubarak et al.,
2007; McChesney et al., 1997). An outbreak of measles in a
rhesus monkey colony led to the isolation of Davis87-wt, a wild-
type MV that retained pathogenicity in monkeys through
exclusive passaging in lymphoid tissue or peripheral blood
mononuclear cells of rhesus macaques (McChesney et al., 1997).
In this study, we have adapted Davis87-wt to growth in three
different cell lines, including avian cells, and identified nucleotide
changes that resulted from these adaptations. The cell culture-
adapted virus stocks were examined for their growth character-
istics in cell culture and for pathogenicity in rhesus macaques.
Results
Development of cell culture-adapted virus stocks
Prior to this work, the Davis87-wt strain was propagated
exclusively in rhesus macaques or rhesus lymphoid cells
(McChesney et al., 1997). Davis87-wt was passaged nine
times in Vero/hSLAM cells to generate the D-V/S stock as
described in Materials and methods. Syncytia, the characteristic
cytopathic effect (CPE) of infection with MV, were visible from
the first passage. Adaptation of Davis87-wt to Vero cells
followed a similar protocol, but a greater starting titer (1000 pfu/
25 cm2 flask instead of 25 pfu/25 cm2 flask) was used, followed
by several blind passages. CPE was first visible at passage five.
Adaptation to Vero cells was carried out twice to generate two
viral stocks, D-VI and D-VII. Two attempts were made to
directly infect primary chicken embryo fibroblasts (CEF) with
Davis87-wt, using 1250 pfu/25 cm2 flask as an inoculum. The
cells were passaged up to nine times without visible CPE. No
MV could be detected by indirect immunofluorescence or by
RT-PCR (data not shown). To establish the CEF-adapted virus
stock, D-CEF, cells were infected at an MOI of 1 with D-V/S
and passaged as described for the Vero cell cultures. Table 1
summarizes the passage history and the titers of the final stocks.
It is important to note that the viruses were not plaque purified.
The high titers suggest that the viruses are well adapted to grow
in their respective cell lines.
Sequence analysis
The complete genomic sequences of all four cell culture-
adapted strains and Davis87-wt were determined. Sequence
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which was responsible for the resurgence of measles in the US
from 1989–1991 (data not shown) (Rota et al., 1992). Davis87-
wt and D-V/S were genetically identical, demonstrating that
nine passages in Vero/hSLAM cells had not selected for
nucleotide changes.
Only one predicted amino acid change was identified in D-
VI, amino acid 30 in the cytoplasmic tail of the H protein was
changed from Leu in Davis87-wt to Pro (Table 2). Nucleotide
12751 had changed from a guanosine in the wild-type virus to a
mix of guanosine and adenosine in the passaged viral stock,
demonstrating that the stocks consisted of a mixture of viral
subpopulations. An adenosine at this position leads to a
predicted amino acid change from Arg to His at amino acid
1173 in the L protein. Two silent nucleotide changes were
detected in D-VI. Sequence analysis of D-VII also detected only
one predicted amino acid change, in the N protein, with amino
acid 23 changed from Gly to Arg. Additionally, D-VII had two
silent changes and three mixed positions, one of which was in
close proximity to the editing site in the P gene, extending the
series of three guanosines at the editing site to four in the
subpopulation that contains this substitution (Table 2).
The only virus stock with multiple, predicted amino acid
substitutions wasD-CEF. TheMprotein contained one predicted
amino acid change from Thr to Ile at position 84. Three predicted
amino acid changes were identified in all three proteins encoded
by the P gene. These included a Val to Ala substitution at amino
acid 102 in the C protein and two mutations affecting amino
acids 110 and 120 in the shared amino terminal domain of P and
V. In addition, D-CEF contained two silent mutations and fiveTable 2
Nucleotide and predicted amino acid differences between the Davis87-wt virus and
Gene Nucleotide a Davis87-wt D-VI b
N 174 G
P 2125 T
2133 T
2134 T
2165 T
2499 C
2708 A
M 3688 C
4306 A
M/F 4873 T
4874 T
F 5667 G
6499 T
H 7345 T C
7359 T C
7360 T C
7482 A
L 9563 A T
10,946 C
11,513 T
12,751 G G/Ad
a Nucleotide position in the 15,894 base genome of Davis87-wt.
b Table lists only positions that differ from Davis87-wt.
c Amino acid change is indicated.
d Mixed nucleotide position (see text).
e The predicted amino acid change at positions with mixed nucleotides with the pmixed positions. Two of these mixed positions were located in
the intergenic trinucleotide (CTT) between the M and F genes,
replacing one or both of the thymidines with cytidines (Table 2).
Aside from these last two mixed positions, there were no
substitutions in any noncoding region of the four cell culture-
adapted viruses, nor were there any amino acid changes to the F
genes. The only nucleotide sequence changes found in the L
genes were silent or mixed positions.
Growth of cell culture-adapted viruses in various cell lines
Indirect immunofluorescence assays demonstrated that
within 24 h after infection, all five viruses produced large
syncytia in B95a cells, a marmoset B lymphoblastoid cell line
expressing the marmoset homolog of hSLAM (Fig. 1).
Similarly, large syncytia were detected after infection of Vero/
hSLAM cells with all five viruses (data not shown). As
expected, the Vero-adapted strains produced large foci of
infection on Vero cells; however, these foci developed after 3
days of incubation. Large plaques were also detectable on Vero
cells infected with D-CEF. The CEF-adapted virus appeared to
spread faster on Vero cells than the Vero-adapted strains. As
expected, the wild-type MV, Davis87-wt, was not able to infect
Vero cells. While Davis87-wt did not produce visible foci in
Vero cells, occasionally, single infected cells were detectable by
indirect immunofluorescence (data not shown). Surprisingly,
small foci of infected cells without any detectable fusion
activity were observed in Vero cells infected with D-V/S. This
difference between Davis87-wt and D-V/S was due to
differences in the input MOI as all infections were carried outcell culture-adapted viral stocks derived from Davis 87 wt
D-VIIb D-CEFb Protein, predicted amino acid change c
A N, Gly23Arg
C P/C/V, silent
C C, Val102Ala
C P/V, Tyr110His
C P/V, Val120Ala
G/C d V, (His232Asp) e, editing site
A/Gd A/Gd P, (Glu301Gly)e
T M, Thr84Ile
A/Gd M, (Asp290Gly)e
T/Cd MF intergenic trinucleotide
T/Cd MF intergenic trinucleotide
A/Gd F, silent
C F, silent
H, silent
H, Leu30Pro
H, Leu30Pro
A/Gd H, (His71Arg)e
L, silent
T L, silent
C L, silent
L, (Arg1173His)e
redicted amino acid from the altered nucleotide shown in parentheses.
Fig. 1. Infection of B95a cells, Vero cells, and CEF with cell culture-adapted viruses. Cells in chamber slides were infected with the indicated viruses at an MOI of 0.1,
except for Davis87-wt, which had to be used at an MOI of 0.001 due to its low titer. At the indicated time points, indirect immunofluorescence assays were performed
with an anti-N monoclonal antibody (green fluorescence). Propidium iodide (red fluorescence) was used to stain the nuclei. Photos were taken with 200×
magnification.
42 B. Bankamp et al. / Virology 373 (2008) 39–50with an MOI of 0.1, except for Davis87-wt, which had to be
used at an MOI of 0.001 due to its low titer. When D-V/S was
used at an MOI of 0.001, no signs of infection were detectable
by indirect immunofluorescence assay (data not shown). A
possible alternative explanation for the difference is that the D-
V/S stock may contain a minor subpopulation that can replicate
in Vero cells. However, no heterogeneous nucleotide positions
were detected during sequencing of the D-V/S viral stock and
this is in contrast to the sequencing results from the other virus
stocks, which clearly contained mixed positions. Therefore, if
there are subpopulations present in D-V/S, they are minor
components of the stock.The ability to infect CEF is limited to vaccine strains of MV
which have been passaged in avian cells (Escoffier and Gerlier,
1999, and data not shown). Only D-CEF produced large foci of
infection on CEF. These foci developed over 4 days and
demonstrated little fusion. Indirect immunofluorescence assays
did not detect any foci of infected cells when the two Vero-
adapted strains were used to infect CEF.
To further analyze the replication potential of the passaged
viruses, growth curves were carried out in Vero cells (Fig. 2).
Davis87-wt could not be tested because of insufficient amounts
of the original virus stock. Viral titers were determined as
TCID50 on Chinese hamster ovary cells expressing hSLAM
Fig. 2. Growth of cell culture adapted virus stocks in Vero cells. Vero cells were
infected with the indicated viruses at an MOI of 0.01. At the indicated time
points, TCID50/ml of cell-associated virus (A) and virus released into the
supernatant (B) were measured on CHO-hSLAM cells. The figure shows one
representative example of three independent experiments.
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greater than 10 5 TCID50/ml by day five for all four viruses
tested (Fig. 2A). D-CEF reproducibly reached the highest titers,
followed by D-VI and D-VII. D-V/S always produced the
lowest cell associated titers, approximately 100-fold lower than
D-CEF. Despite the significant titers of cell-associated virus, D-
V/S released only minimal amounts of virus into the medium
(Fig. 2B). D-CEF consistently demonstrated the highest titers in
the supernatant medium, followed by D-VI and D-VII. These
results indicate that D-V/S does productively infect Vero cells,
but that virus release is restricted.
Receptor usage of cell culture-adapted viruses
CHO cells stably expressing hSLAM or CD46 were infected
with the cell culture-adapted strains and Davis87-wt. Indirect
immunofluorescence assays demonstrated that all viruses
produced large syncytia in CHO-hSLAM cells, but none of
them produced detectable foci on CHO-CD46 cells (Fig. 3).
While individual CHO-CD46 cells expressing MVantigen were
detectable, the infection did not spread to neighboring cells. The
same result was obtained when infecting CHO cells that do not
express either receptor for MV. As a positive control, the MV
vaccine strain, Edmonston-Zagreb, was used to infect CHO-
CD46 cells. This virus produced large syncytia on CHO-CD46
cells, demonstrating the ability of these cells to support MV
replication. These results show that the cell culture-adaptedstrains did not spread in CHO-CD46 cells, demonstrating their
inability to use CD46 as a receptor.
Pathogenesis of cell culture-adapted strains in rhesus
macaques
Juvenile rhesus macaques were infected intranasally and
conjunctivally with 3.2X104 TCID50 of D-V/S, D-VI or D-
CEF. Monkeys were observed for the characteristic rash and
results were compared to historical controls of juvenile
macaques infected with Davis87-wt. All four monkeys infected
with D-V/S developed a typical MV rash, whereas none of the
monkeys infected with D-VI or D-CEF showed clinical signs of
disease (Table 3). RNA was isolated from PBMC taken at day
seven post infection from two monkeys infected with D-VI and
two monkeys infected with D-CEF. PCR fragments were
generated with MV-specific primers and sequenced to confirm
the presence of the nucleotide substitutions in the H gene of D-
VI and the P and M genes of D-CEF. The substitutions were still
present; confirming that the mutations remained stable in the
animals and did not revert to wild-type sequences (data not
shown).
Blood samples were taken on days 0, 7, 14, and 28 post
infection and viral titers in PBMC were determined by co-
cultivation with Raji cells (Fig. 4). In historical controls, PBMC
from macaques infected with Davis87-wt reached peak titers
that were slightly greater than 104 TCID50 per 10
6 PBMC on
day seven post infection and still had detectable titers on day 14.
Titers in monkeys infected with D-VI and D-CEF reached peaks
ranging from 102 (D-CEF) or 103 (D-VI) to 104 TCID50 per
106 PBMC on day seven. Titers in three of four monkeys
infected with D-CEF and two of four infected with D-VI had
fallen below the detection limit on day 14. Macaques infected
with D-V/S demonstrated peak titers ranging from 103 to 105
TCID50 per 10
6 PBMC, and two of four monkeys still had
detectable titers at day 14. No significant differences in viremia
were detectable between monkeys that did and did not develop a
rash. These data demonstrate a slight reduction in peak titer and
duration of viremia in all of the monkeys infected with cell
culture-passaged virus stocks compared to the historical
controls infected with Davis87-wt.
MV infection causes a transient suppression of the immune
system which interferes with the development of an anamnestic
immune response (Griffin, 1995; McChesney et al., 1989). To
test for the ability to mount an immune response against an
unrelated antigen, macaques were re-vaccinated with tetanus
toxoid on day seven after MV infection. Because the macaques
had been vaccinated with tetanus toxoid as infants, this second
vaccination should boost antibody titers unless inhibited by
MV-induced immunosuppression. Antibody titers were com-
pared on days 0 and 21 after tetanus vaccination and expressed
as fold increase (Table 3). Titers in all eight monkeys infected
with D-VI or D-CEF and two monkeys infected with D-V/S
rose at least fourfold, indicating an absence of immunosuppres-
sion. Two out of four monkeys infected with D-V/S had a titer
increase against tetanus toxoid that was fourfold or less,
suggesting that their immune responses had been suppressed.
Fig. 3. Characterization of receptor usage of cell culture-adapted viruses by infection of CHO cells expressing cellular receptors for MV. CHO, CHO-hSLAM, and
CHO-CD46 cells in chamber slides were infected with the indicated viruses at anMOI of 0.1, except for Davis87-wt, which had to be used at an MOI of 0.001 due to its
low titer. At the indicated time points, indirect immunofluorescence assays were performed with an anti-MV N monoclonal antibody (green fluorescence). Propidium
iodide (red fluorescence) was used to stain the nuclei. Photos were taken with 100× magnification. Ed-Zag=Edmonston-Zagreb vaccine strain.
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and CEF-adapted viruses had lost pathogenicity in rhesus
macaques, but the Vero/hSLAM-passaged virus had retained
pathogenicity.Discussion
The results of this study confirm that passage of wild-type
measles viruses in Vero cells results in viruses with reduced
Table 3
Pathogenesis of cell culture-adapted strains in rhesus macaques
Virus Monkey number Rash Fold rise in tetanus
toxoid titer
D-V/S 33808 +a 10
33815 + 40
35231 + 1.25
35234 + 1
D-VI 33407 − 40
33965 − 80
33995 − 32
35220 − 40
D-CEF 33483 − 32
34045 − 8
34175 − 40
34180 − 32
Davis87-wt 33833 + 1
34247 + 1
a (+) indicates presence, (−) absence of rash.
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cells or primate cell lines that contain the receptor for wild-type
measles virus, hSLAM, preserves the virulent phenotype
(Auwaerter et al., 1999; Kobune et al., 1990, 1996). Passage
of viruses in primary human PBMC is impractical, and the B95a
cell line that was used in some of the previous studies is
persistently infected with Epstein Barr Virus. Therefore, the
recently developed Vero/hSLAM cell line may provide a better
substrate for the production of challenge stocks for use inFig. 4. Titers of MV in rhesus peripheral blood mononuclear cells (PBMC) following
and 28 post infection were titrated by co-cultivation with Raji cells. Titers are exprestudies of the pathogenesis of measles virus. The work
presented here shows for the first time that the virulent
phenotype and wild-type sequence of a rhesus-adapted strain
of measles were maintained following passage in Vero/hSLAM
cells. The Vero/hSLAM passaged virus, D-V/S, produced a rash
in all of the infected macaques; however, two of the four
animals did not show evidence of immunosuppression, and the
peak titers of virus in PBMC were slightly lower than those
observed for historical controls. It is unclear whether the D-V/S
stock demonstrated slightly reduced pathogenicity compared to
the Davis87-wt or whether the differences were due to small
variations in titer compared to the historical controls. Historical
controls have demonstrated variability in both the level of
viremia in PBMC and the recall response to tetanus toxoid
vaccination (Premenko-Lanier et al., 2004; Zhu et al., 1997).
Immunosuppression following measles infection can be demon-
strated as suppression of lymphoproliferative responses,
delayed type hypersensitivity, or antibody response (Hirsch et
al., 1984; Premenko-Lanier et al., 2004; Tamashiro et al., 1987).
In this study, immunosuppression was detected by analyzing the
anamnestic response to tetanus toxoid (TT) vaccination. We
have previously used this method to demonstrate a significant
negative correlation between immunosuppression and protec-
tion against measles with experimental DNA vaccines (Pre-
menko-Lanier et al., 2004).
We attempted to repeat the process that was used to derive
the current live attenuated vaccines for measles by adapting ainfection with cell culture-adapted viral stocks. PBMC isolated at days 0, 7, 14,
ssed as log10 of the TCID50/10
6 PBMC. Monkeys are identified by number.
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unable to directly establish an infection in CEF with Davis87-
wt. Instead, a high-titered stock of D-V/S was used successfully
to infect these avian cells. When attempting to generate the
original measles vaccine, Katz et al. (1958) also failed to infect
CEF directly from patient specimens and needed to passage the
original Edmonston isolate 56 times in human cell lines and
embryonated chicken eggs before successfully infecting CEF. It
is interesting to note that, as observed previously (Escoffier and
Gerlier, 1999), the CEF-adapted virus was able to productively
infect Vero cells, while neither of the Vero-adapted strains was
able to replicate in CEF. The cellular receptor used by measles
virus to infect CEF has not been identified.
Both D-VI and D-CEF were attenuated in rhesus
macaques as none of the animals developed the rash or
immunosuppression that was produced by infection with
Davis87-wt. However, for these viruses, the peak viral titers
in PBMC did not differ significantly from the titers following
challenge with D-V/S. Other studies have demonstrated
significantly lower titers in PBMC of macaques infected
with MV vaccine strains compared to titers measured in
monkeys infected with wild-type viruses (Auwaerter et al.,
1999; van Binnendijk et al., 1994). Our results suggest that
D-VI and D-CEF may not have been completely attenuated
after 19–21 passages and that additional passage may lead to
increased attenuation. For this study, we used the minimal
number of passages required for generation of virus stocks
with titers high enough for subsequent experiments. It is also
possible that measurement of viral titers in PBMC may not
be as sensitive as clinical presentation for detection of
changes in viral pathogenicity.
A unique aspect of this report is that all of the viral stocks
were characterized by complete genomic sequencing, which
enabled us to document the genetic changes that accompanied
adaptation of a virulent virus to growth in Vero cells and CEF.
Analysis of these changes may provide clues as to the genetic
basis for the attenuation of measles virus. The mutations in the
cell culture-adapted viruses may affect their fitness. The results
of the growth curves indicate increased fitness in Vero cells as
measured by increased progeny, especially of the D-CEF virus
compared to D-V/S. However, fitness gains in one environment
(cell culture) can lead to fitness loss in another environment
(animal host) (Domingo and Holland, 1997). To measure the
contributions of individual mutations to attenuation and fitness
both in cell culture and in vivo, we are currently constructing
recombinant measles viruses.
Two independent experiments demonstrated that mutations
in different proteins can occur as result of adaptation to Vero
cells, as has been reported previously (Takeda et al., 1998;
Takeuchi et al., 2000), and suggest that there are multiple
pathways to cell culture adaptation and attenuation. The only
amino acid substitution in D-VI compared to Davis87-wt was
found in the cytoplasmic domain of the H protein, a substitution
that would not be expected to affect receptor specificity. This
interpretation was confirmed by the observation that D-VI did
not infect CHO-CD46 cells, indicating that the amino acid
change in the cytoplasmic tail did not allow the virus to useCD46 as a receptor. However, the substitution may affect
interactions between the viral glycoproteins and therefore
fusogenicity of the virus (Cathomen et al., 1998; Plemper et
al., 2002) or it may affect interactions with the M protein and
consequently transport of the glycoproteins to the apical
membrane of polarized cells (Naim et al., 2000). Compared to
Davis87-wt, the only amino acid substitution in D-VII was
located at position 23 of the N protein. The amino terminus of N
is part of N-core, which spans amino acids 1–400 of the 525
amino acid N protein, and is required for encapsidation (Lamb
and Kolakofsky, 2001). Amino acids 4–188 are required for
formation of the soluble N–P complex which provides the
substrate for encapsidation of the genome (Bankamp et al.,
1996).Vero cells lack the ability to produce type I interferons
(Emeny and Morgan, 1979). It has been demonstrated that
adaptation of wild-type MV strains to Vero cells can lead to a
selection of variants that have lost the ability to counteract this
arm of the innate immune system (McKimm and Rapp, 1977).
Since these defective mutants were relatively abundant
(McKimm and Rapp, 1977), it is possible that the loss of
interferon-inhibiting activity confers a replicative advantage in
cell lines that lack interferon. The possibility that the mutations
we described alter the ability of the virus to inhibit part of the
innate immune response is currently under investigation.
The D-CEF stock had four predicted amino acid substitu-
tions compared to Davis87-wt. The change at amino acid 84 of
the M protein of D-CEF is located in close proximity to amino
acid substitutions Pro64Ser and Glu89Lys in the Edmonston
strain of MV. These two substitutions were shown to improve
growth in Vero cells (Miyajima et al., 2004; Tahara et al., 2005)
by enhancing virus assembly (Tahara et al., 2007). This domain
of the M protein may play a role in cell culture adaptation. Also,
mutations in M may affect interactions with F or H and sorting
of these glycoproteins to the apical membrane (Naim et al.,
2000). The substitution found at amino acid 102 in the C protein
of D-CEF falls into a domain that may regulate the replication of
D-CEF because naturally occurring variations between amino
acids 46 and 167 of the C protein affect its ability to down
regulate RNA synthesis (Bankamp et al., 2005). Of the two
substitutions in the P and V proteins of D-CEF, the substitution
at amino acid 110 (Tyr to His) is expected to result in an
impaired ability to inhibit interferon signaling. The same
substitution was found in Edtag, a recombinant virus based on a
laboratory strain of Edmonston. In this virus, the substitution
affected the ability of the P and V proteins to block type I
interferon signaling (Devaux et al., 2006; Ohno et al., 2004).
The V protein has been demonstrated to regulate viral
transcription in a mini-genome replication assay and amino
acids 110–131 played a role in this activity (Witko et al., 2006).
Adaptation of a pathogenic wild-type strain of the closely
related morbillivirus, canine distemper virus (CDV), to canine
footpad keratinocytes induced mutations in the P/V/C and M
proteins as well as the cytoplasmic tail of the H protein, similar
to the results presented in our study (Rivals et al., 2006).
Our results demonstrate that wild-type viruses can adapt to
growth in Vero cells without amino acid changes in the H
protein and without using CD46 as a receptor. Similar results
47B. Bankamp et al. / Virology 373 (2008) 39–50have been reported for Vero cell-adaptation of MV (Kouomou
and Wild, 2002; Nielsen et al., 2001; Takeuchi et al., 2000) and
of CDV (Lednicky et al., 2004; Nielsen et al., 2003). Cell
culture-adapted measles viruses of the Edmonston lineage can
use both hSLAM and CD46 as a receptor, and two substitutions
in the H protein, Gln451Val and Asn481Tyr, have been
implicated as being required for CD46 binding (Erlenhofer et
al., 2002; Lecouturier et al., 1996). The H proteins of Davis87-
wt and all four cell culture-adapted viruses share a Val at amino
acid 451, but have Asn at position 481. The inability of the cell
culture-adapted strains to infect CHO-CD46 cells indicates that
none use CD46 as a receptor. Nevertheless, D-VI, D-VII, and
D-CEF are able to infect Vero cells and replicate to high titers.
These observations provide further support for the existence of a
CD46-independent entry mechanism for Vero cells, possibly via
an unknown third receptor (Andres et al., 2003; Hashimoto et
al., 2002; Takeuchi et al., 2002; Yanagi et al., 2006). Other
reports have presented evidence that the H proteins of wild-type
viruses can bind CD46 with low affinity (Manchester et al.,
2000; Masse et al., 2002); however, the inability of the viral
stocks generated in this study to infect CHO-CD46 cells
suggests that low affinity binding did not occur. The ability to
use the unknown entry mechanism may be present in some
wild-type viruses, since D-V/S could infect Vero cells and
replicate, albeit inefficiently. Primary isolation of wild-type
measles viruses on Vero cells has been reported, though the
process is much more efficient in cell lines that express hSLAM
(Kobune et al., 1990; Ono et al., 2001). The difference in the
ability to infect Vero cells observed between Davis87-wt and D-
V/S was due to the 100-fold lower MOI used for infections with
Davis87-wt. When infection with D-V/S was tested at the lower
MOI, no signs of infection were detectable by indirect
immunofluorescence assay (data not shown).
A search of the GenBank database did not identify any
measles viruses that shared the predicted amino acid substitu-
tions found in the cell culture-adapted viruses described here,
with the exception of the change at amino acid 110 of the P and
V proteins of D-CEF. No definitive nucleotide substitutions
were found in any noncoding regions or in the F or L proteins of
the cell culture-adapted viruses, suggesting that there is strong
selective pressure on these regions of the genome of MV. The
sequencing results demonstrated that some nucleotide positions
in the cell culture-adapted viruses were heterogeneous. The
viral subpopulations that carry the changes may be affected in
their editing frequency (D-CEF, nucleotide 2499) (Hausmann et
al., 1999; Jacques et al., 1994) or expression of the F protein (D-
CEF, nucleotide 4873, 4874) (Barr et al., 1997; Stillman and
Whitt, 1997). However, these positions remained mixed after
many passages suggesting that there is little selective advantage
for either nucleotide and that their relevance for cell culture-
adaptation may be low. It should be noted that the hetero-
geneous positions were detected because the sequence analysis
program failed to call the base. It is likely that the base calling
software did not identify other mixed positions.
Sequence analysis of the complete genomes of the
Edmonston-derived vaccine strains detected nucleotide changes
in both the coding and noncoding regions compared to theprogenitor strain, Ed wt (Parks et al., 2001a,b). Amino acid
substitutions were found in all proteins and a total of eight
amino acid changes were identified as common to all vaccine
viruses compared to Ed-wt (Parks et al., 2001b). Twenty-one
nucleotide substitutions, including five nucleotide substitutions
common to all vaccine strains, were found in the 3′ and 5′
noncoding regions and intergenic regions (Parks et al., 2001a).
In our attempt to repeat this process using viruses with defined
levels of attenuation for rhesus macaques, we have identified a
relatively smaller number of genetic changes that accompanied
host cell adaptation. At present, we are exploring the
consequences of the amino acid substitutions by using
protein-specific, functional in vitro assays and by virus rescue.
Materials and methods
Cells and viruses
Vero, Vero/hSLAM, B95a, CHO, CHO-hSLAM, CHO-
CD46 cells, and primary chicken embryo fibroblasts (CEF)
were maintained in Dulbecco's modified Eagle's medium
supplemented with 10% fetal bovine serum, glutamine,
penicillin, and streptomycin. Medium for CHO cells and
derivative cell lines was further supplemented with MEM
nonessential amino acids (Invitrogen). G418 sulfate (Cellgro)
was used to maintain expression of hSLAM in Vero/hSLAM
cells (0.4 mg/ml) and CD46 in CHO-CD46 (1 mg/ml). Zeocin
(1 mg/ml, Invitrogen) was used to maintain expression of
hSLAM in CHO-hSLAM cells. CHO-hSLAM and CHO-CD46
cell lines were a generous gift of Roberto Cattaneo, Rochester,
MN. The Edmonston-Zagreb strain was provided by D. Ikic,
Institute of Immunology, Zagreb, Croatia and propagated on
Vero cells. The Davis87-wt stock was prepared as described
previously (McChesney et al., 1997). Starting materials for cell
culture adaptation were passages C8 and C9 of Davis87-wt
which had a titer of 5×103 plaque forming units (pfu)/ml in
Vero/hSLAM cells.
Cell culture adaptation
Vero/hSLAM cells in 25 cm2 flasks were infected with
25 pfu of Davis87-wt. When the cytopathic effect (CPE)
involved most of the monolayer, cells were scraped into 1 ml of
supernatant, frozen once at −70 °C and 0.5 μl used to infect a
fresh culture. Vero cells in 25 cm2 flasks were infected with
1000 pfu of Davis87-wt. CEF in 25 cm2 flasks were infected
with 2.1×106 pfu of D-V/S (MOI of 1). Vero cells and CEF
were passaged every 5 days. When CPE involved most of the
monolayer, cells were scraped into 1 ml of supernatant, frozen
once at −70 °C and 10–50 μl used to infect a fresh culture,
which was passaged until CPE developed. Viral titers of the
small intermediate stocks were not measured. The viral titer of
the final seed stock was determined and an MOI of 0.01 or less
used to prepare larger stocks. Viral titers were measured by
plaque assay on Vero/hSLAM cells. To generate a large stock of
D-VII and D-CEF, the penultimate passage of infected cells was
split by trypsinization to produce the final stock.
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Total cellular RNA from infected cells and from 500 μl of the
Davis87-wt stock was isolated using Trizol (Invitrogen). The
MV genome was amplified in four overlapping fragments using
primers based on the sequence of EdmBil (GenBank accession
number Z66517; Radecke et al., 1995). Reverse transcriptase
reactions were performed using Superscript II reverse tran-
scriptase (Invitrogen). PCR was performed with the Elongase
enzyme mix (Invitrogen) according to manufacturer's recom-
mendations for long PCR. The sequence of the termini was
obtained by using a 5′ RACE kit (Invitrogen). The PCR product
representing the 5′ terminus of the genome (trailer) was
sequenced directly. The PCR product representing the 5′
terminus of the antigenome (leader complement) was cloned
into the TA cloning vector (Invitrogen) and 10 clones contain-
ing the complete terminus were sequenced. Fragments were
sequenced with the Big Dye Terminator v1.1 Cycle Sequencing
kit (Applied Biosystems) using primers based on the EdmBil
sequence. Primer sequences are available upon request. To
verify the continued presence of nucleotide substitutions in cell
culture-adapted viruses following passage in rhesus macaques,
1×105 PBMC were isolated from blood taken on day seven
after infection and RNAwas extracted with the Totally RNA kit
(Ambion). The Superscript One-step RT/PCR kit (Invitrogen)
was used to amplify small (300–500) bp PCR fragments
containing the substitutions identified in the cell culture-adapted
strains. Presence of the substitutions was verified by sequencing
the PCR products. All sequence data were analyzed with the
Sequencher program (Gene Codes Corporation) and version
11.1 of the sequence analysis software package of the
University of Wisconsin Genetics Computer Group (Devereux
et al., 1984). GenBank accession numbers are EU293548,
EU293549, EU293550, EU293551, and EU293552.
Immunofluorescence assays
Cells were seeded on chamber slides (NalgeNunc LabTek)
and infected with an MOI of 0.1 of the cell culture-adapted
strains or an MOI of 0.001 of Davis87-wt because of its low
titer. Cells were fixed with 3.7% formaldehyde (Fisher
Scientific) in PBS for 5 min at RT, followed by permeabilization
with 0.25% Triton-X-100 (Sigma) in PBS for 15 min at RT. A
monoclonal antibody directed against MV N protein was used
for detection (Chemicon), followed by an Oregon green-labeled
goat anti-mouse secondary antibody (Molecular Probes). For
counterstaining, 0.5 μg/ml propidium iodide (Molecular
Probes) was added to the secondary antibody dilution. A
SPOT RT camera (Diagnostic Instruments) and the SPOT
Advanced program were used for photography. Separate photos
of the green and red fluorescence were merged using the SPOT
Advanced program.
Growth curve measurements
Vero cells in 6 well dishes (Corning) were infected at an MOI
of 0.01. At various time points post infection, supernatant wascleared of floating cells by centrifugation for 5 min at 500×g at
4 °C in a tabletop centrifuge. Cells were scraped into 1 ml of
fresh medium and cells or supernatants frozen once at −70 °C.
Viral titers were determined by inoculating CHO-hSLAM cells
in 96 well dishes with serial 10-fold dilutions of the sample.
After 3 days of incubation at 37 °C, CPE was detected by
staining with crystal violet-formaldehyde (0.013% crystal
violet, 2.5% ethanol, 10% formaldehyde in 0.01 M PBS) for
5 min at room temperature. CHO-hSLAM cells were chosen for
titration since MV infection causes increased cell lysis
compared to Vero-hSLAM cells, which simplifies detection of
CPE. TCID50 (50% tissue culture infectious dose) was
determined using the method of Reed and Muench (Reed and
Muench, 1938).
Infection of rhesus macaques and titration on Raji cells
Colony-bred male and female juvenile rhesus macaques
(Macaca mulatta), seronegative for measles virus, simian
type D retroviruses, simian T-cell lymphotrophic virus, and
simian immunodeficiency virus, were housed in accordance
with the American Association for Accreditation of
Laboratory Animals Care. The investigators adhered to the
guidelines of the Committee on Care and Use of Laboratory
Animals, National Research Council. For each virus tested,
four animals were inoculated conjunctivally and intranasally
with 3.2×104 TCID50 as described (McChesney et al.,
1997). Infectious center assays to quantitate viremia were
carried out on Raji cells as described previously (Zhu et al.,
1997). One week after MV inoculation, all animals were
vaccinated subcutaneously with unconcentrated tetanus
toxoid (Colorado Serum Company) at 20 μl/kg body weight.
Tetanus antibody titers on days 0 and 21 were determined
by ELISA as described (Premenko-Lanier et al., 2004). A
fourfold rise in titer was used as a cutoff value to determine
significant changes in tetanus antibody titers.
Acknowledgments
The authors appreciate technical support provided by
Lindsay Margolies. This work was supported by NIH grant
RR00169 to The California National Primate Research Center
and by Cooperative Agreement U10/CCU923373 from the
Centers for Disease Control and Prevention (CDC). Its contents
are solely the responsibility of the authors and do not
necessarily represent the official view of the CDC.References
Andres, O., Obojes, K., Kim, K.S., ter Meulen, V., Schneider-Schaulies, J.,
2003. CD46- and CD150-independent endothelial cell infection with wild-
type measles viruses. J. Gen. Virol. 84 (Pt. 5), 1189–1197.
Anonymous, 2006. Progress in reducing global measles death: 1999–2004.
Wkly. Epidemiol. Rec. 81 (10), 90–94.
Auwaerter, P.G., Rota, P.A., Elkins, W.R., Adams, R.J., DeLozier, T., Shi, Y.,
Bellini, W.J., Murphy, B.R., Griffin, D.E., 1999. Measles virus infection in
rhesus macaques: altered immune responses and comparison of the virulence
of six different virus strains. J. Infect. Dis. 180 (4), 950–958.
49B. Bankamp et al. / Virology 373 (2008) 39–50Bankamp, B., Horikami, S.M., Thompson, P.D., Huber, M., Billeter, M., Moyer,
S.A., 1996. Domains of the measles virus N protein required for binding to P
protein and self-assembly. Virology 216 (1), 272–277.
Bankamp, B., Wilson, J., Bellini, W.J., Rota, P.A., 2005. Identification of
naturally occurring amino acid variations that affect the ability of the
measles virus C protein to regulate genome replication and transcription.
Virology 336 (1), 120–129.
Barr, J.N., Whelan, S.P., Wertz, G.W., 1997. Role of the intergenic dinucleotide
in vesicular stomatitis virus RNA transcription. J. Virol. 71 (3), 1794–1801.
Buckland, R., Wild, T.F., 1997. Is CD46 the cellular receptor for measles virus?
Virus Res. 48 (1), 1–9.
Cathomen, T., Naim, H.Y., Cattaneo, R., 1998. Measles viruses with altered
envelope protein cytoplasmic tails gain cell fusion competence. J. Virol. 72
(2), 1224–1234.
Cattaneo, R., Kaelin, K., Baczko, K., Billeter, M.A., 1989. Measles virus editing
provides an additional cysteine-rich protein. Cell 56 (5), 759–764.
Devaux, P., von Messling, V., Songsungthong, W., Springfeld, C., Cattaneo, R.,
2006. Tyrosine 110 in the measles virus phosphoprotein is required to block
STAT1 phosphorylation. Virology.
Devereux, J., Haeberli, P., Smithies, O., 1984. A comprehensive set of sequence
analysis programs for the VAX. Nucleic Acids Res. 12 (1 Pt 1), 387–395.
Domingo, E., Holland, J.J., 1997. RNAvirus mutations and fitness for survival.
Annu. Rev. Microbiol. 51, 151–178.
Dorig, R.E., Marcil, A., Chopra, A., Richardson, C.D., 1993. The human CD46
molecule is a receptor for measles virus (Edmonston strain). Cell 75 (2),
295–305.
ElMubarak, H.S., Yuksel, S., van Amerongen, G., Mulder, P.G., Mukhtar, M.M.,
Osterhaus, A.D., de Swart, R.L., 2007. Infection of cynomolgus macaques
(Macaca fascicularis) and rhesus macaques (Macaca mulatta) with different
wild-type measles viruses. J. Gen. Virol. 88 (Pt 7), 2028–2034.
Emeny, J.M., Morgan, M.J., 1979. Regulation of the interferon system: evidence
that Vero cells have a genetic defect in interferon production. J. Gen. Virol.
43 (1), 247–252.
Erlenhoefer, C., Wurzer, W.J., Loffler, S., Schneider-Schaulies, S., ter Meulen,
V., Schneider-Schaulies, J., 2001. CD150 (SLAM) is a receptor for measles
virus but is not involved in viral contact-mediated proliferation inhibition.
J. Virol. 75 (10), 4499–4505.
Erlenhofer, C., Duprex, W.P., Rima, B.K., ter Meulen, V., Schneider-Schaulies,
J., 2002. Analysis of receptor (CD46, CD150) usage by measles virus. J.
Gen. Virol. 83 (Pt 6), 1431–1436.
Escoffier, C., Gerlier, D., 1999. Infection of chicken embryonic fibroblasts by
measles virus: adaptation at the virus entry level. J. Virol. 73 (6), 5220–5224.
Griffin, D.E., 1995. Immune responses during measles virus infection. Curr.
Top. Microbiol. Immunol. 191, 117–134.
Griffin, D.E., 2001. Measles virus, In: Knipe, D.M., Howley, P.M. (Eds.), 4th ed.
Fields Virology, vol. 1. Lippincott Williams & Wilkins, Philadelphia, PA,
pp. 1401–1441. 2 vols.
Hashimoto, K., Ono, N., Tatsuo, H., Minagawa, H., Takeda, M., Takeuchi, K.,
Yanagi, Y., 2002. SLAM (CD150)-independent measles virus entry as
revealed by recombinant virus expressing green fluorescent protein. J. Virol.
76 (13), 6743–6749.
Hausmann, S., Garcin, D., Delenda, C., Kolakofsky, D., 1999. The versatility of
paramyxovirus RNA polymerase stuttering. J. Virol. 73 (7), 5568–5576.
Hirsch, R.L., Griffin, D.E., Johnson, R.T., Cooper, S.J., Lindo de Soriano, I.,
Roedenbeck, S., Vaisberg, A., 1984. Cellular immune responses during
complicated and uncomplicated measles virus infections of man. Clin.
Immunol. Immunopathol. 31 (1), 1–12.
Hsu, E.C., Dorig, R.E., Sarangi, F., Marcil, A., Iorio, C., Richardson, C.D.,
1997. Artificial mutations and natural variations in the CD46 molecules
from human and monkey cells define regions important for measles virus
binding. J. Virol. 71 (8), 6144–6154.
Hsu, E.C., Iorio, C., Sarangi, F., Khine, A.A., Richardson, C.D., 2001. CDw150
(SLAM) is a receptor for a lymphotropic strain of measles virus and may
account for the immunosuppressive properties of this virus. Virology 279
(1), 9–21.
Jacques, J.P., Hausmann, S., Kolakofsky, D., 1994. Paramyxovirus mRNA
editing leads to G deletions as well as insertions. EMBO J. 13 (22),
5496–5503.Katz, S.L., Milovanovic, M.V., Enders, J.F., 1958. Propagation of measles
virus in cultures of chick embryo cells. Proc. Soc. Exp. Biol. Med. 97 (1),
23–29.
Kobune, F., Sakata, H., Sugiura, A., 1990. Marmoset lymphoblastoid cells as a
sensitive host for isolation of measles virus. J. Virol. 64 (2), 700–705.
Kobune, F., Takahashi, H., Terao, K., Ohkawa, T., Ami, Y., Suzaki, Y., Nagata,
N., Sakata, H., Yamanouchi, K., Kai, C., 1996. Nonhuman primate models
of measles. Lab. Anim. Sci. 46 (3), 315–320.
Kouomou, D.W., Wild, T.F., 2002. Adaptation of wild-type measles virus to
tissue culture. J. Virol. 76 (3), 1505–1509.
Lamb, R.A., Kolakofsky, D., 2001. Paramyxoviridae: the viruses and their
replication, In: Knipe, D.M., Howley, P.M. (Eds.), 4th ed. Fields Virology,
vol. 1. Lippincott Williams & Wilkins, Philadelphia, PA, pp. 1305–1340.
2 vols.
Lecouturier, V., Fayolle, J., Caballero, M., Carabana, J., Celma, M.L.,
Fernandez-Munoz, R., Wild, T.F., Buckland, R., 1996. Identification of
two amino acids in the hemagglutinin glycoprotein of measles virus
(MV) that govern hemadsorption, HeLa cell fusion, and CD46 down-
regulation: phenotypic markers that differentiate vaccine and wild-type
MV strains. J. Virol. 70 (7), 4200–4204.
Lednicky, J.A., Meehan, T.P., Kinsel, M.J., Dubach, J., Hungerford, L.L.,
Sarich, N.A., Witecki, K.E., Braid, M.D., Pedrak, C., Houde, C.M., 2004.
Effective primary isolation of wild-type canine distemper virus in MDCK,
MV1 Lu and Vero cells without nucleotide sequence changes within the
entire haemagglutinin protein gene and in subgenomic sections of the fusion
and phospho protein genes. J. Virol. Methods 118 (2), 147–157.
Liszewski, M.K., Post, T.W., Atkinson, J.P., 1991. Membrane cofactor protein
(MCP or CD46): newest member of the regulators of complement activation
gene cluster. Annu. Rev. Immunol. 9, 431–455.
Manchester, M., Eto, D.S., Valsamakis, A., Liton, P.B., Fernandez-Munoz, R.,
Rota, P.A., Bellini, W.J., Forthal, D.N., Oldstone, M.B., 2000. Clinical
isolates of measles virus use CD46 as a cellular receptor. J. Virol. 74 (9),
3967–3974.
Masse, N., Barrett, T., Muller, C.P., Wild, T.F., Buckland, R., 2002.
Identification of a second major site for CD46 binding in the hemagglutinin
protein from a laboratory strain of measles virus (MV): potential
consequences for wild-type MV infection. J. Virol. 76 (24), 13034–13038.
McChesney, M.B., Fujinami, R.S., Lerche, N.W., Marx, P.A., Oldstone, M.B.,
1989. Virus-induced immunosuppression: infection of peripheral blood
mononuclear cells and suppression of immunoglobulin synthesis during
natural measles virus infection of rhesus monkeys. J. Infect. Dis. 159 (4),
757–760.
McChesney, M.B., Miller, C.J., Rota, P.A., Zhu, Y.D., Antipa, L., Lerche, N.W.,
Ahmed, R., Bellini, W.J., 1997. Experimental measles: I. Pathogenesis in the
normal and the immunized host. Virology 233 (1), 74–84.
McKimm, J., Rapp, F., 1977. Variation in ability of measles virus plaque
progeny to induce interferon. Proc. Natl. Acad. Sci. U. S. A. 74 (7),
3056–3059.
Miyajima, N., Takeda, M., Tashiro, M., Hashimoto, K., Yanagi, Y., Nagata, K.,
Takeuchi, K., 2004. Cell tropism of wild-type measles virus is affected by
amino acid substitutions in the P, Vand M proteins, or by a truncation in the
C protein. J. Gen. Virol. 85 (Pt 10), 3001–3006.
Naim, H.Y., Ehler, E., Billeter, M.A., 2000. Measles virus matrix protein
specifies apical virus release and glycoprotein sorting in epithelial cells.
EMBO J. 19 (14), 3576–3585.
Naniche, D., Varior-Krishnan, G., Cervoni, F., Wild, T.F., Rossi, B., Rabourdin-
Combe, C., Gerlier, D., 1993. Human membrane cofactor protein (CD46)
acts as a cellular receptor for measles virus. J. Virol. 67 (10), 6025–6032.
Nielsen, L., Andersen, M.K., Jensen, T.D., Blixenkrone-Moller, M., Bolt, G.,
2003. Changes in the receptor binding haemagglutinin protein of wild-type
morbilliviruses are not required for adaptation to Vero cells. Virus Genes 27
(2), 157–162.
Nielsen, L., Blixenkrone-Moller, M., Thylstrup, M., Hansen, N.J., Bolt, G.,
2001. Adaptation of wild-type measles virus to CD46 receptor usage. Arch.
Virol. 146 (2), 197–208.
Ohno, S., Ono, N., Takeda, M., Takeuchi, K., Yanagi, Y., 2004. Dissection of
measles virus V protein in relation to its ability to block alpha/beta interferon
signal transduction. J. Gen. Virol. 85 (Pt 10), 2991–2999.
50 B. Bankamp et al. / Virology 373 (2008) 39–50Ono, N., Tatsuo, H., Hidaka, Y., Aoki, T., Minagawa, H., Yanagi, Y., 2001.
Measles viruses on throat swabs from measles patients use signaling
lymphocytic activation molecule (CDw150) but not CD46 as a cellular
receptor. J. Virol. 75 (9), 4399–4401.
Parks, C.L., Lerch, R.A., Walpita, P., Wang, H.P., Sidhu, M.S., Udem, S.A.,
2001a. Analysis of the noncoding regions of measles virus strains in the
Edmonston vaccine lineage. J. Virol. 75 (2), 921–933.
Parks, C.L., Lerch, R.A., Walpita, P., Wang, H.P., Sidhu, M.S., Udem, S.A.,
2001b. Comparison of predicted amino acid sequences of measles virus
strains in the Edmonston vaccine lineage. J. Virol. 75 (2), 910–920.
Plemper, R.K., Hammond, A.L., Gerlier, D., Fielding, A.K., Cattaneo, R., 2002.
Strength of envelope protein interaction modulates cytopathicity of measles
virus. J. Virol. 76 (10), 5051–5061.
Premenko-Lanier, M., Rota, P.A., Rhodes, G.H., Bellini, W.J., McChesney,
M.B., 2004. Protection against challenge with measles virus (MV) in
infant macaques by an MV DNA vaccine administered in the presence of
neutralizing antibody. J. Infect. Dis. 189 (11), 2064–2071.
Radecke, F., Spielhofer, P., Schneider, H., Kaelin, K., Huber, M., Dotsch, C.,
Christiansen, G., Billeter, M.A., 1995. Rescue of measles viruses from
cloned DNA. EMBO J. 14 (23), 5773–5784.
Reed, L.J., Muench, H., 1938. A simple method of estimating fifty per cent
endpoints. Am. J. Hyg. 27, 493–497.
Reutter, G.L., Cortese-Grogan, C., Wilson, J., Moyer, S.A., 2001. Mutations in
the measles virus C protein that up regulate viral RNA synthesis. Virology
285 (1), 100–109.
Riddell, M.A., Rota, J.S., Rota, P.A., 2005. Review of the temporal and
geographical distribution of measles virus genotypes in the prevaccine and
postvaccine eras. Virol. J. 2, 87.
Rivals, J.P., Plattet, P., Currat-Zweifel, C., Zurbriggen, A., Wittek, R., 2006.
Adaptation of canine distemper virus to canine footpad keratinocytes
modifies polymerase activity and fusogenicity through amino acid
substitutions in the P/V/C and H proteins. Virology 359 (1), 6–18.
Rota, J.S., Hummel, K.B., Rota, P.A., Bellini, W.J., 1992. Genetic variability of
the glycoprotein genes of current wild-type measles isolates. Virology 188
(1), 135–142.
Rota, J.S., Wang, Z.D., Rota, P.A., Bellini, W.J., 1994. Comparison of sequences
of the H, F, and N coding genes of measles virus vaccine strains. Virus Res.
31 (3), 317–330.
Shaffer, J.A., Bellini, W.J., Rota, P.A., 2003. The C protein of measles virus
inhibits the type I interferon response. Virology 315 (2), 389–397.
Stillman, E.A., Whitt, M.A., 1997. Mutational analyses of the intergenic
dinucleotide and the transcriptional start sequence of vesicular stomatitis
virus (VSV) define sequences required for efficient termination and
initiation of VSV transcripts. J. Virol. 71 (3), 2127–2137.
Tahara, M., Takeda, M., Yanagi, Y., 2005. Contributions of matrix and large
protein genes of the measles virus edmonston strain to growth in
cultured cells as revealed by recombinant viruses. J. Virol. 79 (24),
15218–15225.Tahara, M., Takeda, M., Yanagi, Y., 2007. Altered interaction of the matrix
protein with the cytoplasmic tail of hemagglutinin modulates measles virus
growth by affecting virus assembly and cell-cell fusion. J. Virol. 81 (13),
6827–6836.
Takeda, M., Kato, A., Kobune, F., Sakata, H., Li, Y., Shioda, T., Sakai, Y.,
Asakawa, M., Nagai, Y., 1998. Measles virus attenuation associated with
transcriptional impediment and a few amino acid changes in the polymerase
and accessory proteins. J. Virol. 72 (11), 8690–8696.
Takeuchi, K., Kadota, S.I., Takeda, M., Miyajima, N., Nagata, K., 2003.
Measles virus V protein blocks interferon (IFN)-alpha/beta but not IFN-
gamma signaling by inhibiting STAT1 and STAT2 phosphorylation. FEBS
Lett. 545 (2–3), 177–182.
Takeuchi, K., Miyajima, N., Kobune, F., Tashiro, M., 2000. Comparative
nucleotide sequence analyses of the entire genomes of B95a cell-isolated
and vero cell-isolated measles viruses from the same patient. Virus Genes 20
(3), 253–257.
Takeuchi, K., Takeda, M., Miyajima, N., Kobune, F., Tanabayashi, K., Tashiro,
M., 2002. Recombinant wild-type and edmonston strain measles viruses
bearing heterologous H proteins: role of H protein in cell fusion and host cell
specificity. J. Virol. 76 (10), 4891–4900.
Tamashiro, V.G., Perez, H.H., Griffin, D.E., 1987. Prospective study of the
magnitude and duration of changes in tuberculin reactivity during uncompli-
cated and complicated measles. Pediatr. Infect. Dis. J. 6 (5), 451–454.
Tatsuo, H., Ono, N., Tanaka, K., Yanagi, Y., 2000. SLAM (CDw150) is a
cellular receptor for measles virus. Nature 406 (6798), 893–897.
Tober, C., Seufert, M., Schneider, H., Billeter, M.A., Johnston, I.C., Niewiesk,
S., ter Meulen, V., Schneider-Schaulies, S., 1998. Expression of measles
virus V protein is associated with pathogenicity and control of viral RNA
synthesis. J. Virol. 72 (10), 8124–8132.
van Binnendijk, R.S., van der Heijden, R.W., van Amerongen, G., UytdeHaag,
F.G., Osterhaus, A.D., 1994. Viral replication and development of specific
immunity in macaques after infection with different measles virus strains. J.
Infect. Dis. 170 (2), 443–448.
WHO, 2005. Global measles and rubella laboratory network—update. Wkly.
Epidemiol. Rec. 80 (44), 384–388.
Witko, S.E., Kotash, C., Sidhu, M.S., Udem, S.A., Parks, C.L., 2006. Inhibition
of measles virus minireplicon-encoded reporter gene expression by V
protein. Virology 348 (1), 107–119.
Wolfson, L.J., Strebel, P.M., Gacic-Dobo, M., Hoekstra, E.J., McFarland, J.W.,
Hersh, B.S., 2007. Has the 2005 measles mortality reduction goal been
achieved? A natural history modelling study. Lancet 369 (9557), 191–200.
Yanagi, Y., Ono, N., Tatsuo, H., Hashimoto, K., Minagawa, H., 2002. Measles
virus receptor SLAM (CD150). Virology 299 (2), 155–161.
Yanagi, Y., Takeda, M., Ohno, S., 2006. Measles virus: cellular receptors,
tropism and pathogenesis. J. Gen. Virol. 87 (Pt 10), 2767–2779.
Zhu, Y.D., Heath, J., Collins, J., Greene, T., Antipa, L., Rota, P., Bellini, W.,
McChesney, M., 1997. Experimental measles: II. Infection and immunity in
the rhesus macaque. Virology 233 (1), 85–92.
